HANOVER, Md.--()--Conmed Healthcare Management, Inc. (NYSE Amex: CONM), a leading full service provider of correctional facility healthcare services to county and municipal detention centers, today announced financial results for its third quarter and nine months ended September 30, 2010.
“The quality of the care we provide and our commitment to servicing our customers continues to result in steady growth of our business”
Third Quarter Financial Highlights
- Quarterly net revenue increased 12.8% to a record $15.4 million from $13.6 million in last year's comparable period.
- Operating expenses as a percentage of sales declined 270 basis points to 14.9% from 17.6% in the year-ago period.
- Operating income increased 45% to approximately $481,000, compared to operating income of approximately $331,000 in the year-ago period.
- Finished the quarter with $13.0 million in cash and no debt.
Third Quarter Operating Highlights:
- Announced contract with City of Virginia Beach, Virginia, a new customer, valued at $17.5 million over a five-year term, effective October 1, 2010.
- Announced contract extensions related to 35 existing county and municipal contracts with anniversary dates between January 1, 2010 and August 1, 2010, representing an anticipated 2.6% increase in annual revenues on these contracts as of August 4, 2010.
- Announced promotion of Dr. Stephen Goldberg to Executive Vice President.
- Announced promotion of Dr. Robert Younes to Chief Medical Officer.
Third Quarter Financial Results
Net revenue for the three months ended September 30, 2010 increased $1.7 million, or 12.8%, to a record $15.4 million from $13.6 million in last year's comparable period. The addition of service contracts signed with new jurisdictions since July 1, 2009 accounted for $1.4 million, or 82.3%, of this increase compared to the same period for the prior year. Revenue improvement also resulted from expansion of services provided under a number of existing contracts under which we were providing services prior to July 1, 2009 as well as price increases related to existing service requirements, offset by decreases in other volume related activities, primarily associated with a decrease in revenue adjustments resulting from lower inmate populations.
“The quality of the care we provide and our commitment to servicing our customers continues to result in steady growth of our business,” commented Richard Turner, Chairman and Chief Executive Officer of Conmed. “In the third quarter, we announced the renewals and/or extensions on each of the remaining contracts that we had coming due this year, and we’ve reached an annual run rate of $63 million, which compares to $16.8 million in revenues in the final year that this company operated as a private company, four years ago. We anticipate additional opportunities for continued expansion throughout this year and into 2011.”
Total healthcare expenses for the quarter ended September 30, 2010 were $12.6 million compared to $10.9 million in the year-ago period. The increase in spending for medical expenses in absolute dollars reflects increases primarily from new contracts for medical services both in and out of the facility as well as pharmacy services. Gross profit was essentially flat at $2.8 million, or 18.0% gross margin, compared to $2.7 million, or 20.0% gross margin, last year.
Total operating expenses decreased 4.6% to $2.3 million for the quarter ended September 30, 2010 compared to $2.4 million for the year-ago period. Operating expenses as a percentage of sales declined 270 basis points to 14.9% from 17.6% in the year-ago period. Selling and administrative expenses for the third quarter were $2.1 million or 13.5% of revenue, compared to $2.0 million, or 14.8% of revenue, for the year-ago quarter. The reduction in spending as a percentage of revenue resulted from improved economies of scale as selling and administrative expenses continue to grow at a slower pace than revenue.
Conmed reported operating income of approximately $481,000 in the third quarter compared to operating income of approximately $331,000 in the third quarter last year. Net income was approximately $547,000, or $0.04 per basic and $0.01 per diluted share compared to net income of approximately $854,000, or $0.07 per basic and $0.01 per diluted share, in the year-ago period. The third quarter 2010 net income included a gain of approximately $406,000 for the change in fair value of derivatives due to the decline of Conmed’s common stock from $3.30 at the beginning of the period to $2.95 as of September 30, 2010, as required under derivative accounting for warrants that are indexed to an entity’s own stock **
For the third quarter of 2010, adjusted EBITDA*, a non-GAAP measure, was approximately $858,000 compared to approximately $870,000 in the prior year third quarter.
Year-to-Date Results
Net revenue for the nine months ended September 30, 2010 increased 15.7%, or $6.1 million, to $44.9 million, compared to $38.8 million for last year's comparable period. The addition of service contracts signed with new jurisdictions since January 1, 2009 accounted for $4.7 million, or 77.6%, of the increase in revenue for the nine months ended September 30, 2010 compared to the same period for the prior year. Total healthcare expenses for the nine months ended September 30, 2010 were $36.3 million compared to $30.8 million in the year-ago period. For the nine months ended September 30, 2010, gross profit increased 7.6% to $8.6 million, representing 19.2% gross margin, compared to gross profit of $8.0 million or 20.6% gross margin in last year's same period.
Total operating expenses were $6.9 million, or 15.3% of revenue for the nine months ended September 30, 2010 compared to $7.4 million, or 19.1% of revenue for the year-ago period. Conmed's operating income was $1.7 million compared to operating income of approximately $598,000 in the same period last year. Net income was $1.2 million or $0.09 per basic and $0.06 per diluted share (based on approximately 12.6 million basic and 14.2 million diluted weighted average shares outstanding, respectively) compared to a loss of $(1.4) million, or ($0.11) per basic and fully diluted share (based on approximately 12.5 million basic and diluted weighted average shares outstanding) in the year ago period. For the first nine months of 2010, net income included a gain of approximately $359,000 in fair value of derivatives in the period compared to a $1.7 million loss in fair value of derivatives (outstanding warrants) as of September 30, 2009 as required under derivative accounting for warrants that are indexed to an entity’s own stock**.
For the first nine months of 2010, adjusted EBITDA* increased 11.1% to $3.0 million compared to $2.7 million in the same period last year.
The Company generated $2.2 million in operating cash flow for the nine months ended September 30, 2010, and had $13.0 million in cash and cash equivalents as of September 30, 2010 compared to $11.1 million at December 31, 2009. Days Sales Outstanding (DSO) as of September 30, 2010 was approximately 17 days.
Conference Call
Conmed will host a conference call today, Thursday, November 11, 2010, at 4:30 PM ET. Anyone interested in participating should call 1-877-941-2321 if calling within the United States or 1-480-629-9714 if calling internationally. A re-play will be available until November 18, 2010, which can be accessed by dialing 1-877-870-5176 if calling within the United States or 1-858-384-5517 if calling internationally. Please use passcode 4379080 to access the replay.
The call will also be accompanied live by webcast over the Internet and accessible at http://viavid.net/dce.aspx?sid=00007CA9.
*Use of Non-GAAP Measures
In addition to containing results that are determined in accordance with accounting principles generally accepted in the United States of America (GAAP), this press release also contains non-GAAP financial measures. Adjusted EBITDA, as used in this press release, represents net income (loss) from continuing operations before interest, taxes, depreciation and amortization, adjusted for stock-based compensation and gains or losses on fair value of derivative financial instruments. Adjusted EBITDA is a key indicator used by management to evaluate operating performance. While adjusted EBITDA is not intended to replace any presentation included in the consolidated financial statements under GAAP and should not be considered an alternative to operating performance or an alternative to cash flow as a measure of liquidity, the Company believes this measure is useful to investors in assessing the Company’s capital expenditures and working capital requirements. This calculation may differ in method of calculation from similarly titled measures used by other companies. A reconciliation of adjusted EBITDA to the nearest comparable GAAP financial measure is included in the financial schedules accompanying this press release. The adjusted financial measure, as well as other information in this press release, should be read in conjunction with the Company’s financial statements filed with the Securities and Exchange Commission.
**Derivative Accounting for Warrants that are Indexed to an Entity’s Own Stock:
Effective January 1, 2009, we adopted derivative accounting for warrants that are indexed to an entity’s own stock. We are required to record a non-cash charge to our GAAP results and thus our financial statements will continue to include this charge going forward until certain events occur and/or conditions are met, as defined in the new regulations. As a result of the Company’s adoption of this accounting standard effective January 1, 2009, approximately 1.7 million of our issued and outstanding common stock purchase warrants previously treated as equity pursuant to the derivative treatment exemption were no longer afforded equity treatment and as a result they have been recorded as a liability based on fair value estimates. These common stock purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the Black-Scholes option pricing model and all changes in the fair value of these warrants will be recognized currently in earnings until such time as the warrants are exercised or expire. Between January 1, 2009 and September 30, 2010, we amended 906,570 of the remaining 1,534,667 common stock purchase warrants to remove the provisions that resulted in liability treatment, and such amended common stock purchase warrants are not treated as equity.
About Conmed
Conmed has provided correctional healthcare services since 1984, beginning in the State of Maryland, and currently serves county and municipal correctional facilities in seven states, including Arizona, Kansas, Maryland, Oklahoma, Oregon, Virginia and Washington. For more information, visit us at www.conmedinc.com.
Forward Looking Statements
This press release may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company's plans, objectives, expectations and intentions; and (ii) other statements that are not historical facts including statements which may be identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "projects," "potentially," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control) including, without limitation, the Company's ability to increase revenue and to continue to obtain new contracts, the incurrence of start-up costs associated with new contracts, contract renewals and extensions; inflation exceeding the Company’s projection of the inflation rate of cost of services under multi-year contracts; the ability to obtain bonds; decreases in occupancy levels or disturbances at detention centers; malpractice litigation; the ability to utilize third party administrators for out-of-facility care; compliance with laws and government regulations, including those relating to healthcare; investigation and auditing of our contracts by government agencies; competition; termination of contracts due to lack of government appropriations; material adverse changes in economic and industry conditions in the healthcare market; negative publicity regarding the provision of correctional healthcare services; dependence on key personnel and the ability to hire skilled personnel; influence of certain stockholders; increases in healthcare costs; insurance; completion and integration of future acquisitions; public company obligations; limited liability of directors and officers; the Company’s ability to meet the NYSE Amex continued listing standards; and stock price volatility. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2009. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. The Company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
-Tables Follow-
| CONMED HEALTHCARE MANAGEMENT, INC. | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
|
|
||||||||
|
September 30, 2010
(unaudited) |
December 31, 2009 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 13,008,470 | $ | 11,056,143 | ||||
| Accounts receivable | 2,960,259 | 2,278,074 | ||||||
| Prepaid expenses | 226,638 | 865,261 | ||||||
| Deferred taxes | 111,000 | 102,000 | ||||||
| Total current assets | 16,306,367 | 14,301,478 | ||||||
| PROPERTY AND EQUIPMENT, NET | 594,814 | 605,578 | ||||||
| DEFERRED TAXES | 1,377,000 | 1,381,000 | ||||||
| OTHER ASSETS | ||||||||
| Service contracts acquired, net | 585,250 | 984,000 | ||||||
| Non-compete agreements, net | 286,560 | 436,667 | ||||||
| Goodwill | 6,263,705 | 6,263,705 | ||||||
| Deposits | 11,549 | 11,549 | ||||||
| Total other assets | 7,147,064 | 7,695,921 | ||||||
| $ | 25,425,245 | $ | 23,983,977 | |||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | 2,231,517 | $ | 1,489,498 | ||||
| Accrued expenses | 3,866,770 | 4,146,940 | ||||||
| Taxes payable | 434,383 | 550,000 | ||||||
| Deferred revenue | 827,637 | 1,018,645 | ||||||
| Total current liabilities | 7,360,307 | 7,205,083 | ||||||
| DERIVATIVE FINANCIAL INSTRUMENTS | 658,147 | 1,299,450 | ||||||
| SHAREHOLDERS’ EQUITY | ||||||||
| Preferred stock, no par value; authorized 5,000,000 shares; issued and outstanding zero shares as of September 30, 2010 and December 31, 2009 | -- | -- | ||||||
| Common stock, $0.0001 par value, authorized 40,000,000 shares; issued and outstanding 12,632,593 and 12,629,572 shares as of September 30, 2010 and December 31, 2009, respectively | 1,263 | 1,263 | ||||||
| Additional paid-in capital | 38,584,383 | 37,829,900 | ||||||
| Accumulated deficit | (21,178,855 | ) | (22,351,719 | ) | ||||
| Total shareholders' equity | 17,406,791 | 15,479,444 | ||||||
| $ | 25,425,245 | $ | 23,983,977 | |||||
| CONMED HEALTHCARE MANAGEMENT, INC. | ||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||
| (UNAUDITED) | ||||||||||||||
|
For the Nine |
For the Nine |
For the Three |
For the Three |
|||||||||||
| Service contract revenue | $ | 44,881,099 | $ | 38,775,309 | $ | 15,390,976 | $ | 13,643,317 | ||||||
| HEALTHCARE EXPENSES: | ||||||||||||||
| Salaries, wages and employee benefits | 25,435,552 | 22,138,330 | 8,729,743 | 7,900,235 | ||||||||||
| Medical expenses | 9,301,119 | 7,248,420 | 3,289,376 | 2,485,024 | ||||||||||
| Other operating expenses | 1,540,391 | 1,388,780 | 598,863 | 524,950 | ||||||||||
| Total healthcare expenses | 36,277,062 | 30,775,530 | 12,617,982 | 10,910,209 | ||||||||||
| Gross profit | 8,604,037 | 7,999,779 | 2,772,994 | 2,733,108 | ||||||||||
| Selling and administrative expenses | 6,067,251 | 5,774,101 | 2,076,918 | 2,014,378 | ||||||||||
| Depreciation and amortization | 814,940 | 1,627,951 | 215,241 | 387,392 | ||||||||||
| Total operating expenses | 6,882,191 | 7,402,052 | 2,292,159 | 2,401,770 | ||||||||||
| Operating income | 1,721,846 | 597,727 | 480,835 | 331,338 | ||||||||||
| OTHER INCOME (EXPENSE) | ||||||||||||||
| Interest income | 72,385 | 61,127 | 27,025 | 16,547 | ||||||||||
| Interest (expense) | -- | (7,991 | ) | -- | (819 | ) | ||||||||
| Gain (loss) on fair value of derivatives | 358,633 | (1,688,623 | ) | 406,012 | 755,650 | |||||||||
| Total other income (expense) | 431,018 | (1,635,487 | ) | 433,037 | 771,378 | |||||||||
| Income (loss) before income taxes | 2,152,864 | (1,037,760 | ) | 913,872 | 1,102,716 | |||||||||
| Income tax expense | 980,000 | 402,000 | 366,700 | 249,000 | ||||||||||
| Net income (loss) | $ | 1,172,864 | $ | (1,439,760 | ) | $ | 547,172 | $ | 853,716 | |||||
| EARNINGS (LOSS) PER COMMON SHARE | ||||||||||||||
| Basic | $ | 0.09 | $ | (0.11 | ) | $ | 0.04 | $ | 0.07 | |||||
| Diluted | $ | 0.06 | $ | (0.11 | ) | $ | 0.01 | $ | 0.01 | |||||
| WEIGHTED-AVERAGE SHARES OUTSTANDING | ||||||||||||||
| Basic | 12,630,716 | 12,546,754 | 12,631,919 | 12,606,699 | ||||||||||
| Diluted | 14,246,996 | 12,546,754 | 14,255,523 | 14,183,486 | ||||||||||
| CONMED HEALTHCARE MANAGEMENT, INC. | ||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (UNAUDITED) | ||||||||
|
For the Nine |
For the Nine |
|||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net income (loss) | $ | 1,172,864 | $ | (1,439,760 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities | ||||||||
| Depreciation | 207,493 | 151,951 | ||||||
| Amortization | 607,447 | 1,476,000 | ||||||
| Amortization of long-term customer agreement | 43,750 | -- | ||||||
| Stock-based compensation | 465,516 | 475,597 | ||||||
| (Gain) loss on fair value of derivatives | (358,633 | ) | 1,688,623 | |||||
| Deferred income taxes | (5,000 | ) | (377,000 | ) | ||||
| Changes in working capital components | ||||||||
| (Increase) in accounts receivable | (682,185 | ) | (462,016 | ) | ||||
| Decrease in prepaid expenses | 638,623 | 114,820 | ||||||
| (Increase) in deposits | -- | (275 | ) | |||||
| Increase in accounts payable | 742,019 | 120,886 | ||||||
| Increase (decrease) in accrued expenses | (280,170 | ) | 766,590 | |||||
| Increase (decrease) in income taxes payable | (115,617 | ) | 220,860 | |||||
| Increase (decrease) in deferred revenue | (191,008 | ) | 374,888 | |||||
| Net cash provided by operating activities | 2,245,099 | 3,111,164 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Purchase of property and equipment | (151,801 | ) | (273,178 | ) | ||||
| Stock Purchase of CMHS, LLC | -- | (9,161 | ) | |||||
| Asset purchase | (147,268 | ) | -- | |||||
| Net cash used in investing activities | (299,069 | ) | (282,339 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Payments on line of credit | -- | (100,000 | ) | |||||
| Payments on loans | -- | (93,782 | ) | |||||
| Proceeds from exercise of stock options | 6,297 | 12,000 | ||||||
| Net cash provided by (used in) financing activities | 6,297 | (181,782 | ) | |||||
| Net increase in cash and cash equivalents | 1,952,327 | 2,647,043 | ||||||
| CASH AND CASH EQUIVALENTS | ||||||||
| Beginning | 11,056,143 | 7,472,140 | ||||||
| Ending | $ | 13,008,470 | $ | 10,119,183 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||||||||
| Cash payments for interest | $ | -- | $ | 7,991 | ||||
| Income taxes paid | 1,100,617 | 558,140 | ||||||
| CONMED HEALTHCARE MANAGEMENT, INC. | ||||||||||||||||
| RECONCILIATION OF NET INCOME (LOSS) FROM CONTINUING OPERATIONS | ||||||||||||||||
| TO ADJUSTED EBITDA | ||||||||||||||||
| (UNAUDITED) | ||||||||||||||||
|
For the Nine |
For the Nine |
For the Three |
For the Three |
|||||||||||||
| Net income (loss) | $ | 1,172,864 | $ | (1,439,760 | ) | $ | 547,172 | $ | 853,716 | |||||||
| Income tax expense | 980,000 | 402,000 | 366,700 | 249,000 | ||||||||||||
| Interest income | (72,385 | ) | (61,127 | ) | (27,025 | ) | (16,547 | ) | ||||||||
| Interest expense | -- | 7,991 | -- | 819 | ||||||||||||
| Depreciation and amortization | 814,940 |
1,627,951 |
215,241 | 387,392 | ||||||||||||
| EBITDA | 2,895,419 | 537,055 | 1,102,088 | 1,474,380 | ||||||||||||
| Stock-based compensation | 465,516 | 475,597 | 161,579 | 151,328 | ||||||||||||
| (Gain) loss on fair value of derivatives | (358,633 | ) | 1,688,623 | (406,012 | ) | (755,650 | ) | |||||||||
| Adjusted EBITDA | $ | 3,002,302 | $ | 2,701,275 | $ | 857,655 | $ | 870,058 | ||||||||
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
